Medtronic said that its investigational MiniMed 780G system has delivered improved glycaemic outcomes for individuals with insulin-intensive type 2 diabetes in a clinical trial.
The company is set to unveil data regarding this at the American Diabetes Association’s (ADA) 85th Scientific Sessions in Chicago.
According to the company, participants from the clinical trial experienced an average increase of 8.6% in Time in Range (TIR), reaching 84.9%, surpassing the ADA goal of 70%. Additionally, there was a reduction in HbA1C from 7.7% to 6.9%, aligning with ADA targets for effective diabetes management.
Medtronic diabetes chief medical officer Robert Vigersky said: “As the industry moves toward broader indications of automated insulin delivery systems, we see tremendous potential to improve outcomes and quality of life for millions of people managing type 2 diabetes with insulin.
“Our teams are committed to advancing smart, connected technologies that reduce the daily burden of care and bring precision to insulin therapy like never before.”
In separate findings, the Medtronic LENNY trial, published in The Lancet Diabetes & Endocrinology, evaluated the MiniMed 780G system among young children aged 2-6 years with type 1 diabetes in a home environment.
The trial demonstrated that children using the MiniMed 780G system with SmartGuard achieved a 0.6% lower HbA1C and a 9.9% higher TIR compared to baseline therapy involving manual mode or hybrid closed loop without autocorrections.
Caregivers reported enhanced sleep quality and reduced fear of hypoglycaemia when using the system in auto mode (with SmartGuard) versus manual mode.
A separate single-arm trial conducted across 31 sites assessed the MiniMed 780G system paired with the Simplera Sync sensor among a cohort of 236 individuals with type 2 diabetes.
The results showed positive outcomes across all clinical metrics, including TIR, Time in Tight Range (TITR), and Time Above Range (TAR), compared to the run-in period using hybrid closed loop or open-loop delivery methods. Time Below Range (TBR) remained consistent.
The ADA’s updated 2025 Standards of Care now recommend Automated Insulin Delivery (AID) systems for adults with insulin-intensive type 2 diabetes, acknowledging their potential to enhance clinical outcomes significantly. This supports the growing role of diabetes technology in managing chronic diseases.
For young children with type 1 diabetes, managing the condition presents various challenges for families due to constant monitoring and care demands.
Data from the LENNY trial highlighted improved glycaemic outcomes when using the MiniMed 780G system. The trial involved randomisation into two sequences after a run-in phase, with subjects undergoing a 12-week auto mode period and a subsequent manual mode period across various centres globally.
The study showed no severe hypoglycaemic events and demonstrated an acceptable safety profile.
Caregivers involved in the LENNY trial noted reduced fear of hypoglycemia and improved sleep quality when using auto mode, highlighting potential benefits beyond glucose management.
Currently, the MiniMed 780G system is not indicated for use in type 2 diabetes or children under seven by regulatory bodies like the US Food and Drug Administration (FDA).
